Download Novel Antischizophrenia Treatments full books in PDF, epub, and Kindle. Read online Novel Antischizophrenia Treatments ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Book Synopsis Novel Antischizophrenia Treatments by : Mark A. Geyer
Download or read book Novel Antischizophrenia Treatments written by Mark A. Geyer and published by Springer. This book was released on 2012-10-02 with total page 458 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Book Synopsis Novel Antischizophrenia Treatments by : Mark A. Geyer
Download or read book Novel Antischizophrenia Treatments written by Mark A. Geyer and published by Springer Science & Business Media. This book was released on 2012-10-01 with total page 456 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Recognition that aging is not the accumulation of disease, but rather comprises fundamental biological processes that are amenable to experimental study, is the basis for the recent growth of experimental biogerontology. As increasingly sophisticated studies provide greater understanding of what occurs in the aging brain and how these changes occur
Book Synopsis Brain Aging by : David R. Riddle
Download or read book Brain Aging written by David R. Riddle and published by CRC Press. This book was released on 2007-04-19 with total page 408 pages. Available in PDF, EPUB and Kindle. Book excerpt: Recognition that aging is not the accumulation of disease, but rather comprises fundamental biological processes that are amenable to experimental study, is the basis for the recent growth of experimental biogerontology. As increasingly sophisticated studies provide greater understanding of what occurs in the aging brain and how these changes occur
Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.
Book Synopsis Current Antipsychotics by : Gerhard Gross
Download or read book Current Antipsychotics written by Gerhard Gross and published by Springer. This book was released on 2014-12-14 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.
Based on the understanding of the molecular basis of skin diseases, this truly international book supports the reader to understand the mode of action of new and established therapies. Thus, by explaining the molecular pathology with its applications for therapy, it provides the reader with an up-to-date knowledge of the therapy of skin disease and helps to understand ongoing and new developments in the field. Written and edited by international and renowned dermatology experts from Europe, America and Asia, it also includes regional concepts of therapies. The reader-friendly structure allows the reader to pick up the information quickly; for example, each chapter highlights practical hints for indications and applications. This lavishly illustrated book will support the reader to choose the most appropriate therapy for the patient and to reach a better treatment outcome. It will be an indispensable resource for dermatologists in university departments as well as in clinical practice.
Book Synopsis Therapy of Skin Diseases by : Thomas Krieg
Download or read book Therapy of Skin Diseases written by Thomas Krieg and published by Springer Science & Business Media. This book was released on 2010-03-02 with total page 744 pages. Available in PDF, EPUB and Kindle. Book excerpt: Based on the understanding of the molecular basis of skin diseases, this truly international book supports the reader to understand the mode of action of new and established therapies. Thus, by explaining the molecular pathology with its applications for therapy, it provides the reader with an up-to-date knowledge of the therapy of skin disease and helps to understand ongoing and new developments in the field. Written and edited by international and renowned dermatology experts from Europe, America and Asia, it also includes regional concepts of therapies. The reader-friendly structure allows the reader to pick up the information quickly; for example, each chapter highlights practical hints for indications and applications. This lavishly illustrated book will support the reader to choose the most appropriate therapy for the patient and to reach a better treatment outcome. It will be an indispensable resource for dermatologists in university departments as well as in clinical practice.
This volume presents a series of studies that expand laws, invariants, and principles of psychophysics beyond its classical domain of sensation. This book's goal is to demonstrate the extent of the domain of psychophysics, ranging from sensory processes, through sensory memory and short-term memory issues, to the interaction between sensation and action. The dynamics and timing of human performance are a further important issue within this extended framework of psychophysics: Given the similarity of the various cortical areas in terms of their neuroanatomical structure, it is an important question whether this similarity is paralleled by a similarity of processes. These issues are addressed by the contributions in the present volume using state-of-the-art research methods in behavioral research, psychophysiology, and mathematical modeling. The book is divided into four sections. Part I presents contributions concerning the classical domain of psychophysical judgment. The next two parts are concerned with elementary and higher-order processes and the concluding section deals with psychophysical models. The sections are introduced by guest editorials contributed by independent authors. These editorials present the authors' personals view on the respective section, providing an integrated account of the various contributions or highlighting their focus of interest among them. While also voicing their own and sometimes different point of view, they contribute to the process of discussion that makes science so exciting. This volume should be of great interest to advanced students in neuroscience, cognitive science, psychology, neuropsychology, and related areas who seek to evaluate the range and power of psychological work today. Established scientists in those fields will also appreciate the variety of issues addressed within the same methodological framework and their multiple interconnections and stimulating "cross-talk."
Book Synopsis Psychophysics Beyond Sensation by : Christian Kaernbach
Download or read book Psychophysics Beyond Sensation written by Christian Kaernbach and published by Psychology Press. This book was released on 2004-05-20 with total page 526 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume presents a series of studies that expand laws, invariants, and principles of psychophysics beyond its classical domain of sensation. This book's goal is to demonstrate the extent of the domain of psychophysics, ranging from sensory processes, through sensory memory and short-term memory issues, to the interaction between sensation and action. The dynamics and timing of human performance are a further important issue within this extended framework of psychophysics: Given the similarity of the various cortical areas in terms of their neuroanatomical structure, it is an important question whether this similarity is paralleled by a similarity of processes. These issues are addressed by the contributions in the present volume using state-of-the-art research methods in behavioral research, psychophysiology, and mathematical modeling. The book is divided into four sections. Part I presents contributions concerning the classical domain of psychophysical judgment. The next two parts are concerned with elementary and higher-order processes and the concluding section deals with psychophysical models. The sections are introduced by guest editorials contributed by independent authors. These editorials present the authors' personals view on the respective section, providing an integrated account of the various contributions or highlighting their focus of interest among them. While also voicing their own and sometimes different point of view, they contribute to the process of discussion that makes science so exciting. This volume should be of great interest to advanced students in neuroscience, cognitive science, psychology, neuropsychology, and related areas who seek to evaluate the range and power of psychological work today. Established scientists in those fields will also appreciate the variety of issues addressed within the same methodological framework and their multiple interconnections and stimulating "cross-talk."
The chapters in the book address the problem of reference as it relates to perception and to debates about realism.
Book Synopsis Perception, Realism, and the Problem of Reference by : Athanassios Raftopoulos
Download or read book Perception, Realism, and the Problem of Reference written by Athanassios Raftopoulos and published by Cambridge University Press. This book was released on 2012-04-12 with total page 299 pages. Available in PDF, EPUB and Kindle. Book excerpt: The chapters in the book address the problem of reference as it relates to perception and to debates about realism.
This unique new reference contains the Carcinogenic Potency Database (CPDB), which analyzes results of decades of animal cancer tests, including all Technical Reports of the National Toxicology Program (NTP) and the general published literature. A guide to the literature of animal cancer tests, the CPDB includes references to each published experiment and never-before published analyses. For each of 5,000 long-term experiments on 1,300 chemicals, the user-friendly format includes data on the species, strain, and sex of the test animal; features of experimental protocol such as the route of administration, duration of dosing, dose levels, and duration of the experiment; histopathology and tumor incidence; the shape of the dose-response curve; published author's opinion about the carcinogenicity at each site; and reference to the original publication of the test results. In addition, a measure of carcinogenic potency, the TD50, its statistical significance and confidence limits, are given for each tumor site. An overview is provided of earlier publication updates, such as positivity rates, reproducibility, interspecies extrapolation, and ranking possible carcinogenic hazards. The book also includes a summary of the NTP genetic toxicity test results on 1,500 chemicals, which are referenced to the original publications, including the Salmonella (Ames) test, L5178Y mouse lymphoma cell mutation test, chromosome aberration and sister chromatid exchange tests in cultured Chinese hamster ovary cells, and the sex-linked recessive lethal mutation test in Drosophila melanogaster. An index with chemicals listed by CAS number allows cross referencing between the carcinogenicity and genotoxicity databases, making data easy to find.
Book Synopsis Handbook of Carcinogenic Potency and Genotoxicity Databases by : Lois Swirsky Gold
Download or read book Handbook of Carcinogenic Potency and Genotoxicity Databases written by Lois Swirsky Gold and published by CRC Press. This book was released on 1996-11-26 with total page 840 pages. Available in PDF, EPUB and Kindle. Book excerpt: This unique new reference contains the Carcinogenic Potency Database (CPDB), which analyzes results of decades of animal cancer tests, including all Technical Reports of the National Toxicology Program (NTP) and the general published literature. A guide to the literature of animal cancer tests, the CPDB includes references to each published experiment and never-before published analyses. For each of 5,000 long-term experiments on 1,300 chemicals, the user-friendly format includes data on the species, strain, and sex of the test animal; features of experimental protocol such as the route of administration, duration of dosing, dose levels, and duration of the experiment; histopathology and tumor incidence; the shape of the dose-response curve; published author's opinion about the carcinogenicity at each site; and reference to the original publication of the test results. In addition, a measure of carcinogenic potency, the TD50, its statistical significance and confidence limits, are given for each tumor site. An overview is provided of earlier publication updates, such as positivity rates, reproducibility, interspecies extrapolation, and ranking possible carcinogenic hazards. The book also includes a summary of the NTP genetic toxicity test results on 1,500 chemicals, which are referenced to the original publications, including the Salmonella (Ames) test, L5178Y mouse lymphoma cell mutation test, chromosome aberration and sister chromatid exchange tests in cultured Chinese hamster ovary cells, and the sex-linked recessive lethal mutation test in Drosophila melanogaster. An index with chemicals listed by CAS number allows cross referencing between the carcinogenicity and genotoxicity databases, making data easy to find.
Featuring a unique approach, Nicotinic Receptors in the Nervous System provides integrated coverage of research on neuronal nicotinic systems relevant to smoking addiction and cognitive dysfunction. By bringing together molecular and neurochemical applications, the book provides the key to understanding function and dysfunction of nicotinic systems and how they are significant for disease, addiction, and the development of novel drug treatments. The book presents readers with the basic mechanistic background for these treatments as well as the functional assessment necessary to determine therapeutic effects.
Book Synopsis Nicotinic Receptors in the Nervous System by : Edward D. Levin
Download or read book Nicotinic Receptors in the Nervous System written by Edward D. Levin and published by CRC Press. This book was released on 2001-08-29 with total page 310 pages. Available in PDF, EPUB and Kindle. Book excerpt: Featuring a unique approach, Nicotinic Receptors in the Nervous System provides integrated coverage of research on neuronal nicotinic systems relevant to smoking addiction and cognitive dysfunction. By bringing together molecular and neurochemical applications, the book provides the key to understanding function and dysfunction of nicotinic systems and how they are significant for disease, addiction, and the development of novel drug treatments. The book presents readers with the basic mechanistic background for these treatments as well as the functional assessment necessary to determine therapeutic effects.
Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.
Book Synopsis Current Antipsychotics by : Gerhard Gross
Download or read book Current Antipsychotics written by Gerhard Gross and published by Springer Science & Business Media. This book was released on 2012-11-05 with total page 423 pages. Available in PDF, EPUB and Kindle. Book excerpt: Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.
